20 Eastbourne Terrace
About LivaNova PLCLivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. The company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business franchises: Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.), respectively.
CEO: Damien McDonald
CFO: Vivid Sehgal
Please click here for LivaNova job opportunities.
66 articles with LivaNova PLC
New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment
Recently published data reinforces the ability of Perceval to optimize the surgical approach to aortic valve replacement
The actor advocates for his son and others affected by epilepsy
LivaNova Comments on Proposed Decision Memo from the U.S. Centers for Medicare & Medicaid Services Regarding National Coverage Determination for VNS Therapy for Treatment-Resistant Depression
Final decision to be rendered by CMS in 90 days
LivaNova PLC today announced Thad Huston, Chief Financial Officer, will participate in discussions during the Piper Jaffray 30th Annual Healthcare Conference in New York and at the Berenberg European Conference 2018 in London.
LivaNova PLC today reported results for the quarter ended September 30, 2018.
LivaNova PLC today announced that Damien McDonald, Chief Executive Officer, will present at the Stifel 2018 Healthcare Conference on Tuesday, Nov. 13 in New York at 9:30 a.m. Eastern Standard Time.
The Company will release its third quarter 2018 results prior to the call.
LivaNova Launches International Pivotal Study Evaluating Use of Autonomic Regulation Therapy for Heart Failure
The study is an international, multi-center, randomized trial to evaluate the VITARIA System for the treatment of advanced heart failure.
Announcement comes as Company completes enrollment in PERSIST-AVR Trial for Perceval sutureless aortic valve
LivaNova VNS Therapy System for Drug-Resistant Epilepsy Could Save $77,000 Per Patient Over Five Years
Analysis finds overall cost savings far exceed system-related costs
LivaNova Launches Global Clinical Registry to Assess VNS Therapy Treatment for Drug-Resistant Epilepsy Patients
LivaNova PLC today announced the first implanted patient and official launch of a global registry to evaluate the use of LivaNova’s Vagus Nerve Stimulation Therapy® (VNS Therapy) System for patients with drug-resistant epilepsy
Company now focused on INTERLUDE CE Mark trial, building upon positive patient outcomes
LivaNova PLC reported results for the quarter ended June 30, 2018.
LivaNova PLC will host a conference call to discuss its second quarter 2018 results on Wednesday, Aug. 1, 2018 at 1 p.m. London time (8 a.m. Eastern Daylight Time).
LivaNova Receives FDA Clearance and Completes First Implant for its MEMO 4D Semi-rigid Mitral Annuloplasty Ring
MEMO 4D now offers a broader range of ring sizes from 24 to 42mm allowing an additional patient population with mitral regurgitation (“MR”) to be treated
Elected by the Company’s shareholders to its board of directors during its June 12 annual general meeting.
LivaNova PLC today announced that Japan’s Ministry of Health, Labour and Welfare has approved the Company’s Perceval® sutureless aortic heart valve to treat aortic valve disease.
LivaNova PLC announced company executives will present at two upcoming healthcare conferences.
LivaNova Comments on the U.S. Centers for Medicare & Medicaid Services’ Reconsideration of its National Coverage Determination for VNS Therapy for Treatment-Resistant Depression
LivaNova PLC issued a statement in regard to the U.S. Centers for Medicare & Medicaid Services’ (“CMS”) publication.
LivaNova PLC reported results for the quarter ended March 31, 2018.